Evidence map›Paper›PMID 41108431›Full record

Trial reportInternational journal of colorectal disease2025

Management of symptomatic uncomplicated diverticular disease (SUDD) of the colon with Clostridium butyricum CBM588 versus rifaximin: a retrospective cross-sectional study.

Riccardo Urgesi, Cristiano Pagnini, Fernando De Angelis, Amjad Khan, Lorella Pallotta, Gianfranco Fanello, Pavlos Antypas, Maria Carla Di Paolo, Giuseppe Villotti, Alexander Bertuccioli and 4 more

Abstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Riccardo UrgesiGastroenterology Department, S. Giovanni Addolorata Hospital, Rome, Italy.
Cristiano PagniniGastroenterology Department, S. Giovanni Addolorata Hospital, Rome, Italy. cpagnini@hsangiovanni.roma.it.
Fernando De AngelisSapienza University of Rome, Rome, Italy.
Amjad KhanDepartment of Biochemistry, Liaquat University of Medical & Health Sciences (LUMHS), Jamshoro, Pakistan.
Lorella PallottaGastroenterology Department, S. Giovanni Addolorata Hospital, Rome, Italy.
Gianfranco FanelloGastroenterology Department, S. Giovanni Addolorata Hospital, Rome, Italy.
Pavlos AntypasGastroenterology Department, S. Giovanni Addolorata Hospital, Rome, Italy.
Maria Carla Di PaoloGastroenterology Department, S. Giovanni Addolorata Hospital, Rome, Italy.
Giuseppe VillottiGastroenterology Department, S. Giovanni Addolorata Hospital, Rome, Italy.
Alexander BertuccioliDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Davide SistiDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Francesco Di PierroMicrobiota International Clinical Society, Turin, Italy.
Nicola ZerbinatiDepartment of Medicine and Technological Innovation, University of Insubria, Varese, Italy.
Maria Giovanna GrazianiGastroenterology Department, S. Giovanni Addolorata Hospital, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSymptomatic uncomplicated diverticular disease (SUDD) is a chronic condition frequently characterized by abdominal pain, bloating, and altered bowel habits. While cyclic rifaximin is commonly used for symptom control, interest is growing in the potential role of probiotics. This study aimed to compare the clinical outcomes of patients with SUDD treated with either Clostridium butyricum CBM588® or cyclic rifaximin over a 12-month period.

methodsThis retrospective cross-sectional study included 70 patients with a confirmed diagnosis of SUDD, treated between 2023 and 2024. Patients were divided into two groups based on treatment received: Group A (CBM588® daily for 12 months) and Group B (cyclic rifaximin 400 mg bid for 7 days per month). Clinical data, symptom profiles, and occurrence of diverticulitis were collected and compared. The primary outcome was the reduction of SUDD-related symptoms, and the secondary outcome was the incidence of acute diverticulitis episodes during follow-up.

resultsA total of 56 patients completed the 12-month follow-up (31 in Group A, 25 in Group B). No significant difference was observed in the rate of symptomatic flares between groups (19.4% vs. 20%, p = 0.7). However, a significantly higher proportion of patients in the CBM588

conclusionIn this retrospective comparison, Clostridium butyricum CBM588

Indexed as

Clostridium butyricumColonDiverticular DiseasesRifaximinAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeRifaximinButyrateClostridium butyricumProbioticRifaximinSCFAsShort chain fatty acidsSUDDSymptomatic uncomplicated diverticular disease

Identifiers

PMID41108431
PMCPMC12535492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.